Title : IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.

Pub. Date : 2009 Dec

PMID : 19340428






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies. fludarabine ADAM metallopeptidase domain 29 Homo sapiens
2 Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies. Cyclophosphamide ADAM metallopeptidase domain 29 Homo sapiens